Magnus Medical, Inc., a medical machine firm and developer of mind stimulation know-how for therapy of neuropsychiatric problems, at the moment introduced it obtained 510(ok) clearance from the US Meals & Drug Administration (FDA) for the SAINTTM Neuromodulation System for the therapy of main depressive dysfunction (MDD) in adults who’ve failed to realize passable enchancment from prior antidepressant medicines within the present episode.
“Magnus’ SAINT know-how is groundbreaking and will assist many sufferers with main depressive dysfunction (MDD) who haven’t responded to therapy with antidepressants,” mentioned Alan F. Schatzberg, MD, the Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at Stanford College, and a Previous President of the American Psychiatric Affiliation. “The therapy results noticed with SAINT therapy within the double-blind, randomized managed trial that was revealed within the American Journal of Psychiatry had been dramatic, speedy, and incessantly sustained by the research follow-up interval. The know-how might lead to a elementary change within the therapy method to sufferers with refractory MDD and has the potential to scale back each the morbidity and mortality related to the dysfunction.”
This FDA clearance of the SAINT Neuromodulation System for despair is admittedly thrilling information. That is extra than simply clearance of one other machine. This clearance expands the way in which we will use TMS to deal with despair. The older approaches typically took six weeks for despair to reply, whereas this method noticed remission from despair in simply 5 days. That opens up many new potentialities to make use of SAINT in hospitalized sufferers, for sufferers who current to the emergency room, and with totally different schedules in clinics.”
Mark S. George, MD, distinguished professor of Psychiatry, Radiology and Neuroscience, and director of the Mind Stimulation Division, Psychiatry on the Medical College of South Carolina
The American Journal of Psychiatry revealed outcomes from a double-blinded randomized managed trial (RCT) evaluating SAINT that exhibits 79% of individuals within the energetic therapy arm entered remission from their despair in comparison with 13% within the sham therapy arm.
The SAINT Neuromodulation System, which obtained Breakthrough System Designation from the FDA, a program meant to assist sufferers obtain extra well timed entry to breakthrough applied sciences with the potential to supply more practical therapy for life-threatening or debilitating circumstances than earlier therapies, is a novel innovation that’s considerably impacting the therapy of extreme despair. For the primary time, superior imaging applied sciences mixed with customized focusing on and novel stimulation patterns have yielded a brand new type of individualized neurostimulation for folks with treatment-resistant despair.
“We are actually on the forefront of an unlimited enchancment within the care of treatment-resistant despair, due to the work of the Magnus group and all these whose efforts have led to the SAINT know-how. Right this moment’s FDA’s clearance for the SAINT Neuromodulation System is a serious milestone in our long-term journey to revive and maintain psychological well being,” mentioned Brett Wingeier, Ph.D., co-founder and CEO of Magnus. “Extra broadly, we stay up for seeing this work make a optimistic affect for the thousands and thousands of individuals affected by neuropsychiatric illness. Our medical analysis program will proceed to yield extra insights into how customized neuromodulation can restore wholesome neural exercise throughout all kinds of psychological well being circumstances.
“We count on the business launch of our SAINT Neuromodulation System to start later in 2023 on a restricted foundation, for which we’re constructing a waitlist and fascinating with an amazing variety of instructing establishments, hospitals, clinics, clinicians, and medical professionals,” continued Dr. wing vulture
The SAINT Neuromodulation System makes use of structural and useful magnetic resonance imaging (MRI) to tell a proprietary algorithm that identifies the optimum anatomic goal for centered neurostimulation in folks with MDD. This new method is delivered on an accelerated timeline and is exactly tailor-made to every individual’s mind connectivity.
